Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials

References

• Lyman GH, Kuderer NM, Crawford J, Dale DC. Prophylactic granulocyte colony-stimulating factor (G-CSF) in cancer patients receiving chemotherapy: a meta-analysis (abstract 07–059). 17th Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology International Symposium, Geneva, Switzerland: 2005
   Google Scholar
• Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963–77
   PubMed Web of Science ®Google Scholar
• Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin’s lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d’Etude des Lymphomes de l’Adulte). Ann Oncol 1993;4:651–6
   Google Scholar
• Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901–6
   PubMed Web of Science ®Google Scholar
• Crawford J. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 2003;30:24–30
   PubMed Web of Science ®Google Scholar
• Budman DR. Dose and schedule as determinants of outcomes in chemotherapy for breast cancer. Semin Oncol 2004;31:3–9
   PubMed Web of Science ®Google Scholar
• Crawford J, Wolff D, Dale DC, et al. Assessment of neutropenic risk in cancer patients receiving systemic chemotherapy: results from a prospective nationwide registry [abstract 29]. 2004 MASCC/ISOO International Symposium. 2004
   Google Scholar
• Lyman GH, Berndt ER, Kallich JD, et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 2005;8:149–56
   PubMed Web of Science ®Google Scholar
• Smith TC, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–205
   Web of Science ®Google Scholar
• Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916–24
   Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258–66
   PubMed Web of Science ®Google Scholar
• Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164–70
   PubMed Web of Science ®Google Scholar
• Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319–24
   Google Scholar
• Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727–31
   PubMed Web of Science ®Google Scholar
• Green MD, Koelbl H, Baselga J, et al. A randomized double- blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29–35
   PubMed Web of Science ®Google Scholar
• Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178–84
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Bleecker G, Crawford J, et al. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemo-therapy. Eur J Cancer 1993;29A(Suppl 7):S23–S30
   PubMedGoogle Scholar
• Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999;354:1896–900
   PubMed Web of Science ®Google Scholar
• Kubista E, Glaspy J, Holmes FA, et al. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer 2003;3:391–8
   PubMedGoogle Scholar
• Hedges LV, Olkin I. Statistical Methods for Meta-analysis. Orlando, FL: Academic Press, 1985
   Google Scholar
• Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004;50:129–46
   PubMed Web of Science ®Google Scholar
• Cheng AC, Stephens DP, Currie BJ. Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev 2004;CD004400
   Google Scholar
• Sharma DC. Pegfilgrastim lowers side-effects of chemotherapy. Lancet Oncol 2004;5:461
   PubMed Web of Science ®Google Scholar
• Anonymous. Pegfilgrastim (Neulasta) for prevention of febrile neutropenia. Med Lett Drugs Ther 2002;44:44–5
   PubMed Web of Science ®Google Scholar
• Morstyn G, Foote M, Walker T, Molineux G. Filgrastim (r-metHuG-CSF) in the 21st century: SD/01. Acta Haematol 2001;105:151–5
   PubMed Web of Science ®Google Scholar
• Willis F, Pettengell R, Woll PJ, et al. Pegfilgrastim alone successfully mobilizes peripheral CD34+ cells in chemotherapy-naive subjects with solid tumors. J Support Oncol 2005; 3:66–7
   Google Scholar
• Vogel C, Rader M, Tyulandin S, et al. Pegfilgrastim nearly abrogates occurrence of neutropenic events early in the course of chemotherapy: results of a phase II, randomized, double-blind, placebo-controlled study of patients with breast cancer receiving docetaxel. J Support Oncol 2005;3:58–9
   Google Scholar
• Engert A, Doehner H, Ho AD, et al. Pegfilgrastim supports delivery of BEACOPP chemotherapy administered every 14 days. J Support Oncol 2005;3:48–9
   Google Scholar
• Lopez A, de Sevilla AF, Castaigne S, et al. Pegfilgrastim supports delivery of CHO-R chemotherapy administered every 14 days: a randomized phase II study. J Support Oncol 2005;3:46–7
   Google Scholar
• Bosi A, Szer J, Kassis J, et al. A multicenter, double-blind, randomized, phase II trial comparing pegfilgrastim with filgrastim as an adjunct to chemotherapy for acute myeloid leukemia. J Support Oncol 2005;3:42–3
   Google Scholar
• Siena S, Piccart MJ, Holmes FA, et al. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer. Oncol Rep 2003;10:715–24
   PubMed Web of Science ®Google Scholar
• Holmes FA, Jones SE, O’Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002;13:903–9
   Google Scholar
• Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21:514–19
   PubMed Web of Science ®Google Scholar
• Grigg A, Solal-Celigny P, Hoskin P, et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 2003;44:1503–8
   Google Scholar
• Engert A, Bredenfeld H, Dohner H, et al. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin’s lymphoma: results of a phase II study. Haematologica 2006;91:546–9
   PubMed Web of Science ®Google Scholar
• Meza LA, Green MD, Hackett JR, et al. Filgrastim-mediated neutrophil recovery in patients with breast cancer treated with docetaxel and doxorubicin. Pharmacotherapy 2003;23:1424–31
   PubMed Web of Science ®Google Scholar
• Piccirillo N, De Matteis S, Sora F, et al. Granulocyte-colony stimulating factor after autologous CD34+ immunoselected peripheral blood stem cell transplantation. Haematologica 2004;89:1144–6
   PubMedGoogle Scholar
• Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18: 2522–8
   PubMed Web of Science ®Google Scholar
• Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10: 427–37
   Google Scholar
• Meza LA, Charu V, Campos L, Davis D, Xie F. Pegfilgrastim and filgrastim patterns of use in community oncology practices: results of the ACCEPT study [abstract no. 6113]. 41st Annual Meeting of the American Society of Clinical Oncology Annual Meeting, May 13–17, 2005, Orlando, FL
   Google Scholar
• Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 2006;40:402–7. Epub 2006 Feb 21
   Google Scholar
• von Minckwitz G, Blohmer JU, Lohr A, et al. Primary prophylaxis with 3 weekly pegfilgrastim and ciprofloxacin effectively prevent (febrile) neutropenia and infection during neoadjuvant chemotherapy and docetaxel/doxorubicin/cyclophosphamide (TAC) in breast cancer patients. American Society of Clinical Oncology Annual Meeting, May 13–17, 2005, Orlando, FL
   Google Scholar
• Heckinger EA. Cost minimization analysis of filgrastim (G-CSF) versus pegfilgrastim (peg-G-CSF) for stage II-IV breast cancer patients receiving chemotherapy: assessments based on third-party and societal perspectives [abstract no. 2116]. American Society of Clinical Oncology Annual Meeting, May 31 – Jun 3; 2003, Chicago, IL
   Google Scholar